Figure 5.

Agonistic micelles salvage ischemic brain tissue by eradicating ROS. (A) Representative in vivo T2W-MRI of the ischemic mouse brain at 1, 4, 7, and 14 day PI of PBS, EDV-AM, or EDV-PM with the same EDV dose (0.078 mg/mouse) via i.v.. Above treatments were conducted at 6 h post-stroke model establishment. The ischemic regions at 4 and 14 days post treatment were marked by yellow dashes. (B) The ratio between ischemic and whole brain volume at selected times post treatments (n = 4 or 5 mice per group). ## P < 0.01 vs. PBS group, * P < 0.05 vs. free EDV group. (C) Fluorescence microscopic images displaying ROS levels in ischemic brain striatum at 24 h and 7 days post treatments. Intracerebral ROS were visualized by the i.v. injected dihydroethidium (HEt) that was oxidized by ROS to ethidium (Et) with red color fluorescence. (D) Quantification of ROS levels in ischemic brain striatum at 24 h and 7 days post treatments (n = 12 slices from 4 mouse models). (E) Fluorescence microscopic images of ischemic brain striatum stained by Tunnel kit or immunostained by caspase-3 antibody at 14 days post treatments. Tunnel + or caspase-3 immunofluorescence was displayed in green and nuclei were in blue (n = 12 slices from 3 animal models). (F) Tunnel + and active caspase-3 fluorescence intensities in the ipsilesional striatum post treatments (n = 12 slices from 4 mouse models). ## P < 0.01, * P < 0.05. Scale bar, 100 μm.